Trials / Completed
CompletedNCT05007860
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability. | Vaccines administered per standard of care |
Timeline
- Start date
- 2020-07-16
- Primary completion
- 2021-06-30
- Completion
- 2023-06-30
- First posted
- 2021-08-17
- Last updated
- 2023-07-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05007860. Inclusion in this directory is not an endorsement.